Analysis of Multiple Sclerosis Drug Pricing Undercuts Drug Makers’ Bogus “Innovation” Rhetoric A new study published in the American Academy of Neurology finds the staggering price of medications to treat multiple sclerosis (MS), a rare neurological disorder, is driven largely by profit motivations – not research and development (R&D). These findings undermine Big Pharma’s…
Political Courage Needed to Deliver on Drug Prices By Lauren Aronson Real Clear Health November 22, 2019 The egregious pricing behavior of pharmaceutical giants has sparked a crisis of prescription…
Survey Finds Overwhelming Majorities of Swing State Voters Blame Drug Makers for Rising Prices and Want Congress to Pass Bipartisan Reforms Before Year End For Immediate Release Contact: Jon Conradi…
Nine in Ten Surveyed Adults Believe Rx Prices “Much Higher” Or “Somewhat Higher” Than Reasonable A new Gallup survey demonstrates the rising toll of out-of-control prescription drug prices…
Drug Makers Cry ‘False Narrative’ Over Latest Repot Highlighting Toll of the Industry’s Egregious Pricing Practices Last week, the Centers for Medicare & Medicaid Services (CMS) released a…
Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices Top Brand Name Drug Makers Best Earnings Forecasts While Evading Accountability And that’s a wrap! Three weeks of earnings…
Solutions to Reform Medicare Part D, Increase Competition and Boost Transparency Have Broad Bipartisan Support, Should Be Swiftly Passed THE CRISIS OF RISING PRESCRIPTION DRUG PRICES The…
Brand Name Drug Giant Completes Sweep of Big Pharma Companies Who Beat Expectations After Hiking Prices Earnings reports for the third quarter of the year provide the latest evidence that Big Pharma…
Good Times Rolling for Brand Name Drug Makers, Two More Top Earnings Forecasts After Increasing Prices Two more brand name giants – Bristol-Myers Squibb and Sanofi – topped earnings expectations…
Big Pharma’s Earnings Keep Rising Off of Price Hikes To no one’s surprise, two more brand name drug manufacturers, GlaxoSmithKline (GSK) and Amgen both topped earnings expectations for the third…